ADVERTISEMENT
4 /5 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Sarepta acquires five muscular dystrophy gene therapies from Myonexus

by Ryan Cross
May 13, 2018 | APPEARED IN VOLUME 96, ISSUE 20

Sarepta Therapeutics will pay $60 million up front for access to five gene-therapy candidates under development by Myonexus Therapeutics to treat specific forms of muscular dystrophy. Sarepta made a name for itself in treating muscular dystrophy after U.S. FDA approval of its drug eteplirsen in 2016. Myonexus, a spin-off from Nationwide Children’s Hospital in Columbus, Ohio, just raised its first $2.5 million in seed funding in December. The new firm could earn up to $45 million in additional milestone payments in the deal with Sarepta.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment